Leukopenia and neutropenia in chronic hepatitis C patients with various underlying combination antiviral therapy

The aim of this research is the study of the dynamics of the content of leukocytes and neutrophils in the blood of patients with chronic hepatitis C combination therapy against standard or pegylated interferon combined with ribavirin. Before treatment, as well as at different stages of combination antiviral therapy were studied absolute numbers of leukocytes and blood neutrophils in patients with CHC. In addition, studied the relationship between the dynamics of the content of white blood cells and blood neutrophils and the initial clinical and laboratory parameters (gender, age, body mass index (BMI), the genotype of the virus, the level of viremia, initial level of leukocytes and neutrophils, ALT, histological activity index, the degree of fibrosis) and option of combination therapy. Showing that the reduction of leukocytes and neutrophils have been observed from the second week of treatment, regardless of the option of combination therapy. Application PIFN-α-2а caused significantly more pronounced leukopenia and neutropenia compared with a simple treatment of IFN-α-2а. Furthermore, the development of neutropenia associated with the achievement of sustained virological response in both antiviral schemes therapy. Also we onsider prognostic criteria, indicating the possible development of 
severe leuco-and neutropenia during treatment: age older than 45 years, the high initial activity of replicative virus (>800 000 IU / ml).

1. Лобзин, Ю.В. Вирусные гепатиты: клиника, диагностика, лечение / Ю.В. Лобзин [и др.]. – СПб.: Фолиант, 2003. – 192 с.

2. Fried, M.W. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection / M.W. Fried [et al.] // N. Engl. J. Med. – 2002. – V. 347. – Р. 975–982.

3. Manns, M.P. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial / M.P. Manns [et al.] //Lancet. – 2001. – V. 358. – P. 958–965.

4. Никитин, И.Г. Лечение хронического гепатита С: вчера, сегодня, завтра / И.Г. Никитин // Росс. журн. гастроэнтерол., гепатол., коло проктол. – 2002. – № 6. – С. 11–16.

5. Kowdley, K.V. Hematologic side effects of interferon and ribavirin therapy / K.V. Kowdley // J. Clin. Gastroenterol. – 2005. – V. 39, Suppl. – P. S. 3–8.

6. Mark, A. Interferons play a central role in the natural defense and therapeutic management of hepatitis C: a re view / A. Mark, R.N. Outzen // Internet J. Gastroenterol. – 2007. – V. 5 (2). – P. 24–48

7. Ong, J.P. Managing the hemotologic side effects of antiviral therapy for chronic hepatitis C: anrmia, neutropenia, and thrombocytopenia / J.P. Ong, Z.M. Younossi //Cleveland Clin. J. Med. – 2004. – V .71, Suppl. 3. – P. S17–S.21

8. Sulkowski, M.S. Management of the hematologic complications of hepatitis С therapy / M.S. Sulkowski // Clin. Liver. Dis. – 2005. – V. 9. – P. 601–616.

9. Pellicano, R. Autoimmune manifestation during interferon therapy in patients with chronic hepatitis C: the hepatologist’s view / R. Pellicano [et al.] // Minerva gastroenterol. dietol. –2005. – V. 51. – P. 55–61.

10. Davis, G.L. Early virologic response to treatment with peg interferon alfa-2b plus ribavirin in patients with chronic hepatitis C / G.L. Davis [et al.] // Hepatology. – 2003. –V. 38. – P. 645–652.

11. Peck-Radosavljevic, M. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha / M. Peck-Radosavljevic [et al.] // Gastroenterology. – 2002. – V. 123. –P. 141–151.